Peter Schmid

Professor Peter Schmid is a Professor of Cancer Medicine, Centre Lead of the Centre of Experimental Cancer Medicine, and Director of the Barts Breast Cancer Centre. He leads translational research in breast cancer, focusing on clinical trials from phase I to III.

Research Focus

His research aims to improve breast cancer care through trials investigating immunotherapy combinations (e.g., pembrolizumab, atezolizumab), targeted agents, antibody-drug conjugates, and biomarker-driven concepts across all disease stages. Key interests include overcoming therapy resistance and developing preoperative treatment platforms.

Publication Trends

Recent publications (2018-2020) concentrate on phase 3 clinical trials for triple-negative breast cancer. Predominant themes include immunotherapy-chemotherapy combinations, first-line metastatic treatments, and efficacy assessments of drugs like pembrolizumab and atezolizumab.

Awards and Leadership

• FRCP (Fellow of the Royal College of Physicians)

Major Funding

• BARBICAN: Phase II neoadjuvant trial with ipatasertib + atezolizumab (Roche, 2018-2022)
• ECLIPSE: Phase II immunotherapy trial for ER+/HER2- breast cancer (Roche, 2017-2022)
• Barts Experimental Cancer Medicine Centre (£2M, CRUK/NIHR, 2017-2022)
• Circulating Biomarkers analysis (£499,652, Barts Charity, 2015-2022)

Professional Activities

• Clinical Director, Barts Breast Cancer Centre
• Chair, ESMO Breast Cancer Faculty
• NICE Clinical Expert (Royal College of Physicians nominee)
• ECMC Strategy Group member
• Contributor to international breast cancer guidelines

Laboratory and Team Leadership

He directs the Centre of Experimental Cancer Medicine and Barts Breast Cancer Centre, overseeing translational research teams focused on biomarker discovery and trial design.